Shire's Takhzyro Gets European Nod For Hereditary Angioedema
Zacks Investment Research | Dec 02, 2018 09:47PM ET
Shire plc (NASDAQ:SHPG) announced that the European Commission (EC) has granted marketing approval to Takhzyro (lanadelumab) subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Takhzyro is the first monoclonal antibody to get approval for the preventive treatment of HAE in patients aged 12 years and older in the European Union. The recommended starting dose is 300 mg lanadelumab every two weeks.
HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling) in various parts of the body.
Notably, Takhzyro received approval for the same indication in the United States in August 2018 and in Canada in September 2018.
The European approval was supported by data from a phase III HELP study, which showed that patients taking Takhzyro 300 mg every two weeks had an 87% reduction in mean monthly HAE attacks versus placebo, while the patients taking Takhzyro 300 mg every four weeks had 73% reduction in attacks.
A pre-specified, exploratory analysis showed that 44% of the patients (n=27) receiving Takhzyro 300 mg every two weeks had zero attacks compared to placebo for the 26-week treatment period. Further, a post hoc analysis of the 16-week period from day 70 to day 182 showed that 77% of patients (n=26) treated with Takhzyro in the same dosage arm of the study were attack-free compared to placebo.
Shares of Shire have increased 14.1% year to date against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.